Caris Life Sciences, Inc. $CAI Stock Holdings Boosted by Lazard Asset Management LLC

Lazard Asset Management LLC increased its position in Caris Life Sciences, Inc. (NASDAQ:CAI) by 26.0% during the first quarter, Holdings Channel reports. The fund owned 305,911 shares of the company’s stock after purchasing an additional 63,132 shares during the quarter. Lazard Asset Management LLC’s holdings in Caris Life Sciences were worth $5,470,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. MetLife Investment Management LLC grew its position in Caris Life Sciences by 84.0% in the 4th quarter. MetLife Investment Management LLC now owns 1,654 shares of the company’s stock worth $45,000 after purchasing an additional 755 shares during the last quarter. Global Retirement Partners LLC raised its holdings in shares of Caris Life Sciences by 99,900.0% during the fourth quarter. Global Retirement Partners LLC now owns 1,000 shares of the company’s stock valued at $27,000 after buying an additional 999 shares during the last quarter. Sterling Capital Management LLC boosted its position in shares of Caris Life Sciences by 128.3% during the first quarter. Sterling Capital Management LLC now owns 1,927 shares of the company’s stock worth $34,000 after buying an additional 1,083 shares during the period. PNC Financial Services Group Inc. grew its holdings in Caris Life Sciences by 839.4% in the 1st quarter. PNC Financial Services Group Inc. now owns 1,644 shares of the company’s stock worth $29,000 after buying an additional 1,469 shares in the last quarter. Finally, Police & Firemen s Retirement System of New Jersey increased its position in Caris Life Sciences by 15.0% in the 4th quarter. Police & Firemen s Retirement System of New Jersey now owns 11,932 shares of the company’s stock valued at $322,000 after acquiring an additional 1,560 shares during the period.

Insider Buying and Selling at Caris Life Sciences

In other news, Director Jon Halbert acquired 68,000 shares of the company’s stock in a transaction dated Friday, May 15th. The shares were bought at an average price of $14.56 per share, with a total value of $990,080.00. Following the purchase, the director owned 704,598 shares of the company’s stock, valued at approximately $10,258,946.88. This represents a 10.68% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Jeff L. Vacirca acquired 31,050 shares of the business’s stock in a transaction dated Monday, May 11th. The stock was purchased at an average price of $16.15 per share, with a total value of $501,457.50. Following the acquisition, the director owned 49,671 shares of the company’s stock, valued at approximately $802,186.65. This trade represents a 166.75% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. 50.00% of the stock is currently owned by company insiders.

Caris Life Sciences Price Performance

Shares of NASDAQ:CAI opened at $16.09 on Friday. The stock has a market cap of $4.55 billion and a price-to-earnings ratio of -2.11. The company has a debt-to-equity ratio of 0.64, a current ratio of 7.05 and a quick ratio of 6.52. Caris Life Sciences, Inc. has a 12 month low of $14.19 and a 12 month high of $42.50. The stock’s 50 day moving average price is $16.98 and its 200 day moving average price is $19.07.

Caris Life Sciences declared that its board has authorized a stock buyback plan on Monday, June 8th that allows the company to buyback $100.00 million in shares. This buyback authorization allows the company to buy up to 2.1% of its stock through open market purchases. Stock buyback plans are often an indication that the company’s management believes its stock is undervalued.

Wall Street Analysts Forecast Growth

CAI has been the topic of several recent analyst reports. BTIG Research reaffirmed a “buy” rating and set a $32.00 target price on shares of Caris Life Sciences in a research note on Thursday, July 2nd. Weiss Ratings raised Caris Life Sciences from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, May 11th. Jefferies Financial Group started coverage on shares of Caris Life Sciences in a research note on Monday, April 13th. They set a “buy” rating and a $28.00 price objective on the stock. Robert W. Baird set a $22.00 price objective on shares of Caris Life Sciences in a report on Friday, May 8th. Finally, Evercore set a $25.00 target price on shares of Caris Life Sciences in a research report on Monday, July 6th. Six research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Caris Life Sciences currently has a consensus rating of “Hold” and a consensus price target of $26.11.

Caris Life Sciences Profile

Caris Life Sciences (NASDAQ: CAI) is a molecular science company focused on advancing precision medicine in oncology. The company develops and delivers comprehensive molecular profiling services designed to identify actionable biomarkers across DNA, RNA and protein modalities. Its clinical services are intended to support oncologists in treatment decision-making by matching patients to targeted therapies, immunotherapies and relevant clinical trials based on tumor biology.

Caris provides laboratory-based diagnostic testing and related interpretive reports, combining high-throughput sequencing and other molecular technologies with bioinformatic analysis.